Tauklarify imaging is an FDA-approved brain PET scan that finds tau tangles in adults with cognitive impairment evaluated for Alzheimer's disease. Primary care patients can avoid overreading headlines by treating the result as one staging clue, not a diagnosis. Tauklarify uses florquinitau F 18, a radioactive tracer that sticks to clumped tau so tangles light up on PET.
Lantheus Holdings reports in the FDA approval announcement that FDA approved it on Aug. 14, 2026 for this specific use. It adds tau information alongside amyloid PET, memory testing, and clinical judgment.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the scan add?
- Who is a candidate?
- Why do strong accuracy numbers still need caution?
- What should you ask before agreeing?
What does the scan add?
A tau scan helps characterize disease stage after a doctor already suspects Alzheimer's disease. Amyloid buildup can appear early and stay stable, while tau spread tracks more closely with symptoms. Seeing tau adds context about where a person may sit in that process.
It does not replace other tools. Doctors still need history, exams, cognitive tests, and often amyloid results. A scan image alone cannot explain memory loss.
Who is a candidate?
Only adults with cognitive impairment who are being evaluated for Alzheimer's disease meet the approved use. It is not for routine screening, family-risk checks, or mild forgetfulness without a clinical workup. The Alzheimer's Association criteria treat biomarkers as support for clinical evaluation, not a substitute.
A primary care visit is the right filter. The doctor checks medications, sleep, mood, thyroid, hearing, and other causes of confusion first. Referral for tau PET comes only when Alzheimer's evaluation remains appropriate.
Why do strong accuracy numbers still need caution?
In two blinded-read studies with 617 participants and five readers, NeurologyLive reports in its approval coverage positive agreement of 68%-88% and negative agreement of 93%-99%. Readers also agreed well on positive versus negative scans. Those numbers look reassuring at a glance.
The comparison groups were clearer than many clinic cases. Pharmacy Times notes in its approval report that studies mainly contrasted amyloid-negative unimpaired people with amyloid-positive impaired people. Accuracy may drop in early or intermediate stages, where tau burden is lower and harder to classify. A negative scan does not necessarily exclude tau pathology, and a positive scan does not necessarily confirm disease, so uncertain cases need more evaluation.
What should you ask before agreeing?
Ask what decision the scan would change. Common uses include clarifying diagnosis, guiding specialist referral, or informing trial eligibility. If the plan stays the same either way, delay imaging.
Safety events were uncommon in 1,734 subjects, with headache in 0.7% and nausea in 0.2%. The product is not established for non-Alzheimer tau disorders. Bring a medication list, symptom timeline, and a family member who knows daily function.
- Ask what other tests come first
- Ask how amyloid status affects interpretation
- Ask about radiation exposure and non-Alzheimer tau limits
- Ask where the scan is read and who explains it
- Ask what follow-up happens after a mixed or borderline result
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: How Primary Care Patients Can Avoid Overreading the Headline
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: How Primary Care Patients Can Avoid Overreading the Headline
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: How Primary Care Patients Can Avoid Overreading the Headline
